Compare TransMedics Group Inc (TMDX) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while YieldMax TSLA Option Income Strategy ETF trades at $25.63. The key difference: TransMedics Group Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| TMDX | TSLY | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $150.42 | $48.25 |
52-Week Low | $61.99 | $25.07 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
TSLY, the YieldMax TSLA Option Income Strategy ETF, trades at $25.07, down 2.57% today amid a bearish technical signal. The ETF generates high income through weekly distributions, with recent dividends ranging from $0.26 to $0.52 per share, but faces criticism for capping upside during Tesla rallies. Its strategy relies on synthetic Tesla exposure and covered call overlays, producing an annualized yield near 52.65%, though distributions are largely return of capital.
The outlook is cautious due to structural limitations that sacrifice capital appreciation for income, with risks including volatility from Tesla's performance and option strategy complexity. Investors prioritizing yield may find value, but those seeking growth could underperform Tesla's equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
